Skip to main content
. 2023 Apr 13;15(8):2279. doi: 10.3390/cancers15082279

Table 3.

Characteristics of the idelalisib-induced colitis cases reported to the French Pharmacovigilance Network.

Patient Characteristics n (%)
Age—years mediane (range) 71 (65–78)
Sex—male: female 32:14
Type of hemopathy
  • -

    CLL

  • -

    B-NHL

 26 (56.5%)
20 (43.5%)
Anticancer drug treatments
  • -

    Idelalisib alone

  • -

    Idelalisib associated with anti-CD20

 27 (58.7%)
19 (41.3%)
Time to first digestive symptoms—days 122 (74–212)
Time to specific management—days 20 (6-30)
Colitis seriousness

  • Hospitalization

  • Life-threatening condition

  • Death

 43 (83.5%)
35 (76.1%)
4 (8.7%)
Colonoscopy findings
  • -

    Unknown

  • -

    Nonspecific inflammatory colitis

  • -

    Erythematous colitis

  • -

    Normal findings

  • -

    Ulcerous colitis

 30
9
4
3
3
Idelalisib management
  • -

    Withdrawn

  • -

    Dose reduction

  • -

    Dose unchanged

 43
2
1
Therapeutic management
  • -

    Glucocorticoids

  • -

    No specific drug

  • -

    Symptomatic treatment

  • -

    Antibiotics

  • -

    Antibiotics and glucocorticoids

 23
14
5
3
1